Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome

Bibliography

• Haylen BT, de Ridder D, Freeman RM, et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010;21(1):5-26
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2013;32(3):230-7
   PubMed Web of Science ®Google Scholar
• Stewart W, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, workproductivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101(11):1388-95
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6(11 Suppl):S574-9
   PubMed Web of Science ®Google Scholar
• Urinary incontinence: The management of urinary incontinence in women. 2013. Available from: https://www.nice.org.uk/guidance/cg171
   Google Scholar
• Fowler CJ, Griffiths D, de Groat W. The neural control of micturition. Nat Rev Neurosi 2008;9(6):453-66
   PubMed Web of Science ®Google Scholar
• Andersson KE. Prospective pharmacologic therapies for the overactive bladder. Ther Adv Urol 2009;1(2):71-83
   PubMedGoogle Scholar
• Yamaguchi O. β3-adrenoceptors in human detrusor muscle. Urology 2002;59:25-9
   PubMed Web of Science ®Google Scholar
• Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol 2013;6:1-16
   PubMedGoogle Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;18(4):CD003781
   Google Scholar
• Wagg A. The cognitive burden of anticholinergics in the elderly – implications for the treatment of overactive bladder. Eur Urol Rev 2012;7(1):42-9
   Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110(11):1767-74
   PubMed Web of Science ®Google Scholar
• Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011;65:567-85
   PubMed Web of Science ®Google Scholar
• Awad SA, Bruce AW, Carro-Ciampi G, et al. Distribution of alpha- and beta-adrenoceptors in human urinary bladder. Br J Pharmacol 1974;50(4):525-9
   PubMed Web of Science ®Google Scholar
• Edmunds CW, Roth GB. The point of attack of certain drugs acting on the periphery. Action on the bladder. J Pharmac Exp Ther 1920;15:189-99
   Google Scholar
• Nergårdh A, Boréus LO, Naglo AS, et al. Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol (Copenh) 1977;40(1):14-21
   PubMedGoogle Scholar
• Larsen JJ. Alpha and beta-adrenoceptors in the detrusor muscle and bladder base of the pig and beta-adrenoceptors in thedetrusor muscle of man. Br J Pharmacol 1979;65(2):215-22
   PubMed Web of Science ®Google Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Possible beta 3-adrenoceptor-mediated relaxation of the human detrusor. Acta Physiol Scand 1998;164(1):117-18
   PubMedGoogle Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126(3):819-25
   PubMed Web of Science ®Google Scholar
• Fujimura T, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol 1999;161(2):680-5
   PubMed Web of Science ®Google Scholar
• Igawa Y, Schneider T, Yamazaki Y. Functional investigation of beta-adrenoceptors in human isolated detrusor focusing on the novel selective beta3-adrenoceptor agonist KUC-7322. Naunyn Schmiedebergs Arch Pharmacol 2012;385(8):759-67
   PubMed Web of Science ®Google Scholar
• Maruyama I, Goi Y, Tatemichi S, et al. Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat. Naunyn Schmiedebergs Arch Pharmacol 2012;385(8):845-52
   PubMed Web of Science ®Google Scholar
• Badawi JK, Uecelehan H, Hatzinger M, et al. Relaxant effects of beta-adrenergic agonists on porcine and human detrusor muscle. Acta Physiol Scand 2005;185(2):151-9
   PubMedGoogle Scholar
• Morita T, Iizuka H, Iwata T, et al. Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J Smooth Muscle Res 2000;36(1):21-32
   PubMedGoogle Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol 2001;165(1):240-4
   PubMed Web of Science ®Google Scholar
• Andersson KE. Overactive bladder–pharmacological aspects. Scand J Urol Nephrol Suppl 2002(210):72-81
   PubMedGoogle Scholar
• Badawi JK, Langbein S. Selective beta-adrenoceptor agonists, calcium antagonists and potassium channel openers as a possible medical treatment of the overactive bladder and urge incontinence. Pharmazie 2006;61(3):175-8
   PubMed Web of Science ®Google Scholar
• Rouget C, Rekik M, Camparo P. Modulation of nerve-evoked contractions by β3-adrenoceptor agonism in human and rat isolated urinary bladder. Pharmacol Res 2014;80:14-20
   PubMed Web of Science ®Google Scholar
• D’Agostino G, Condino A, Calvi P. Involvement of beta3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [3H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol 2015;758:115-22
   PubMed Web of Science ®Google Scholar
• Chapple CR, Dvorak V, Radziszewski P, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J 2013;24:1447-58
   PubMed Web of Science ®Google Scholar
• Chapple CR, Amarenco G, Lopez Aramburu MA, et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn 2013;32:1116-22
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallelgroup, placebo-controlled, multicentre study to assess the efficacy and safety of the beta3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013;82:313-20
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283-95
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296-305
   PubMed Web of Science ®Google Scholar
• Wu T, Duan X, Cao C. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int 2014;93:326-37
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65(4):755-65
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175(3):401-7
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 2015;193(5):1572-80
   PubMed Web of Science ®Google Scholar
• Maruyama I, Tatemichi S, Goi Y, et al. Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther 2012;342(1):163-8
   PubMed Web of Science ®Google Scholar
• Maruyama I, Goi Y, Tatemichi S, et al. Bladder selectivity of the novel β3-agonist ritobegron (KUC-7483) explored by in vitro and in vivo studies in the rat. Naunyn Schmiedebergs Arch Pharmacol 2012;385(8):845-52
   PubMed Web of Science ®Google Scholar
• Maruyama I, Yonekubo S, Tatemichi S, et al. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine. J Smooth Muscle Res 2012;48(5-6):115-24
   PubMedGoogle Scholar
• Study to determine pharmacodynamic effects and pharmacokinetics of KUC 7483 CL in patients with spinal cord injury and neurogenic detrusor overactivity. Available from: https://clinicaltrials.gov/ct2/show/NCT02259751 [Last accessed 18 May 2015]
   Google Scholar
• Available from: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1207/1207.4_U05-2402.pdf [Last accessed 14 July 2015]
   Google Scholar
• A confirmatory study of KUC-7483 in patients with overactive bladder. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01004315 [Last accessed 18 May 2015]
   Google Scholar
• Preliminary Results of Phase III clinical study of KUC-7483. Available from: http://www.kissei.co.jp/e_contents/relation/2010/20100702.html [Last accessed 18 May 2015]
   Google Scholar
• Abe Y, Ota E, Endo T, et al. Absorption, disposition, metabolism, and excretion of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, in rats. Pharmazie 2014;69(12):881-8
   PubMed Web of Science ®Google Scholar
• Abe Y, Ota E, Harada H, et al. Species differences in the metabolism of ritobegron in vitro and assessment of potential interactions with transporters and cytochrome P450 enzymes. Pharmazie 2015;70(1):38-46
   PubMed Web of Science ®Google Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 2007;323(1):202-9
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2012;62(5):834-40
   PubMed Web of Science ®Google Scholar
• Rekik M, Rouget C, Palea S, et al. Bladder and Urethra: Anatomy, Physioloogy and Pharmacology (I) Moderated Poster 283: Effects of combining antimuscarinics and β3-adrenoceptor agonists on contractions induced by electrical field stimulation of rat isolated urinary bladder strips. 2013. Available from: http://www.aua2013.org/abstracts/search.cfm
   Google Scholar
• Tasler S, Baumgartner R, Behr-Roussel D, et al. An aryloxypropanolamine hb3-adrenoceptor agonist as bladder smoothmuscle relaxant. Eur J Pharm Sci 2012;46(5):381-7
   PubMed Web of Science ®Google Scholar
• Termination of co-development of a beta3-adrenoceptor agonist. Available from: http://cs2.toray.co.jp/news/toray/en/newsrrs02.nsf/0/5CFEF3CBDD31178249257D11000E4B09
   Google Scholar
• Kanie S, Otsuka A, Yoshikawa S, et al. Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips. Urology 2012;79(3):744.e1-7
   Google Scholar
• Kanie S, Otsuka A, Yoshikawa S, et al. TRK-380, a novel selective human beta3-adrenoceptor agonist, ameliorates formalin-induced pollakiuria in rats and carbachol-induced bladder contraction in dogs. Urology 2013;82(4):975e7-975e12
   Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Hasebe K, et al. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol 2008;15(12):1072-6
   PubMed Web of Science ®Google Scholar
• Kubota Y, Nakahara T, Yunoki M, et al. Inhibitory mechanism of BRL37344 on muscarinic receptor-mediated contractions of the rat urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2002;366(3):198-203
   PubMed Web of Science ®Google Scholar
• Michel MC. Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder? Naunyn Schmiedebergs Arch Pharmacol 2014;387(3):215-24
   PubMed Web of Science ®Google Scholar